Page 3 - Phil Greenberg News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Life sciences and health tech news roundup: AIlen Institute s new CEO, AI2 s incubator, and more

Life sciences and health tech news roundup: AIlen Institute s new CEO, AI2 s incubator, and more
geekwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from geekwire.com Daily Mail and Mail on Sunday newspapers.

University of washingtonUnited statesNoord hollandFred hutchLance baldoPaul allenJonathan harperPhil greenbergHeather greenleeTodd bishopRui costaYves leurquinAllen instituteAlpine immune sciencesNational institutes of healthUs national institutes of health

Life sciences and health tech news roundup: Cancer care, layoffs, fundings, more

Life sciences and health tech news roundup: Cancer care, layoffs, fundings, more
geekwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from geekwire.com Daily Mail and Mail on Sunday newspapers.

Phil greenbergFred hutchRobert hoodPhilip greenbergFred hutchinson cancer centerFred hutchinson cancer research centerFred hutchinson cancerFred hutch photoPacific northwestSeattle childrenAffinit therapeutics

Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations

Co-founded at Fred Hutchinson Cancer Research Center with Phil Greenberg, M.D., Aude Chapuis, M.D., and Tom Schmitt, Ph.D., and Vida Ventures along with serial entrepreneurs Arjun Goyal, M.D., M.Phil., and Jak Knowles, M.D./ Foundational cell therapy platform builds upon seminal work from co-founders, leveraging a T Cell Receptor (TCR) discovery en

Phil greenbergArjun goyalAude chapuisTom schmittFred hutchinson cancer research centerVida venturesJak knowlesColorectal cancerLung cancerCauses of deathClinical medicinePancreatic cancerTreatment of cancerTumor microenvironment

Affini-T Therapeutics, Inc : Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations

Co-founded at Fred Hutchinson Cancer Research Center with Phil Greenberg, M.D., Aude Chapuis, M.D., and Tom Schmitt, Ph.D., and Vida Ventures along with serial entrepreneurs Arjun Goyal, M.D., M.Phil.

United statesFred hutchinson cancer research centerAl iskandariyahFred hutchAude chapuisImke meyerDavid kranzIan stonePhil greenbergRafi ahmedJuergen eckhardtArjun goyalSusan kaechKathy yiPam sharmaTom schmitt

Cell therapy biotech Affini-T gets $175M; KRAS is lead genomic cancer target

Affini-T Therapeutics is developing new cell therapies for cancer that could overcome limitations of the first generation of cell therapies. The initial genomic cancer targets of the startup are mutations of KRAS and p53, both of which have proven difficult to drug.

United statesAl iskandariyahRoche genentechPhil greenbergPolyomavirus mcpyHumboldt fundParker institute for cancer immunotherapyFred hutchinson cancer research centerVida venturesMerkel cell polyomavirusParker instituteCatalio capital managementAgent capitalAlexandria venture investmentsErasca venturesFred hutchinson cancer research